Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers
Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...
Business Wire15d
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...
Investing7d
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights
On Wednesday, 12 March 2025, Amneal Pharmaceuticals (NASDAQ: AMRX) participated in the Barclays 27th Annual Global Healthcare Conference 2025, where Chairman and CEO Chirag Patel outlined the ...
Houston Chronicle19d
Amneal: Q4 Earnings Snapshot
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...